Evidence map›Paper›PMID 38480688›Full record

ArticleNature communications2024

NME3 is a gatekeeper for DRP1-dependent mitophagy in hypoxia.

Chih-Wei Chen, Chi Su, Chang-Yu Huang, Xuan-Rong Huang, Xiaojing Cuili, Tung Chao, Chun-Hsiang Fan, Cheng-Wei Ting, Yi-Wei Tsai, Kai-Chien Yang and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Chih-Wei ChenInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.ORCID 0000-0002-1401-4820
Chi SuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Chang-Yu HuangInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.ORCID 0000-0001-7430-2085
Xuan-Rong HuangInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Xiaojing CuiliInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.ORCID 0000-0002-3819-2509
Tung ChaoInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.ORCID 0000-0003-3641-4996
Chun-Hsiang FanInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Cheng-Wei TingInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Yi-Wei TsaiInstitute of Pharmacology, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Kai-Chien YangInstitute of Pharmacology, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Ti-Yen YehInstitute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.
Sung-Tsang HsiehInstitute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan.ORCID 0000-0002-3188-8482
Yi-Ju ChenInstitute of Chemistry, Academia Sinica, 11529, Taipei, Taiwan.ORCID 0000-0002-7203-9188
Yuxi FengExperimental Pharmacology Mannheim, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany.
Tony HunterMolecular and Cell Biology Laboratory, Salk Institute, La Jolla, CA, 92037-1002, USA.ORCID 0000-0002-7691-6993
Zee-Fen ChangInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002, Taipei, Taiwan. zfchang@ntu.edu.tw.ORCID 0000-0003-3011-284X
National Taiwan University · TWHeidelberg University · DEInstitute of Chemistry, Academia Sinica · TWSalk Institute for Biological Studies · US

Funding

Histidine phosphorylation as a new target for cancer therapyR35CA242443 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI HUNTER, TONY R. · 2019 to 2025
$7.5M
Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) NSCT 111-2320-B-002-088Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) NSCT 111-2326-B-002-022Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) NSCT 111-2634-F-002-017NCI NIH HHS R35 CA242443U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA242443
6 · The paper itself

Abstract

NME3 is a member of the nucleoside diphosphate kinase (NDPK) family localized on the mitochondrial outer membrane (MOM). Here, we report a role of NME3 in hypoxia-induced mitophagy dependent on its active site phosphohistidine but not the NDPK function. Mice carrying a knock-in mutation in the Nme3 gene disrupting NME3 active site histidine phosphorylation are vulnerable to ischemia/reperfusion-induced infarction and develop abnormalities in cerebellar function. Our mechanistic analysis reveals that hypoxia-induced phosphatidic acid (PA) on mitochondria is essential for mitophagy and the interaction of DRP1 with NME3. The PA binding function of MOM-localized NME3 is required for hypoxia-induced mitophagy. Further investigation demonstrates that the interaction with active NME3 prevents DRP1 susceptibility to MUL1-mediated ubiquitination, thereby allowing a sufficient amount of active DRP1 to mediate mitophagy. Furthermore, MUL1 overexpression suppresses hypoxia-induced mitophagy, which is reversed by co-expression of ubiquitin-resistant DRP1 mutant or histidine phosphorylatable NME3. Thus, the site-specific interaction with active NME3 provides DRP1 a microenvironment for stabilization to proceed the segregation process in mitophagy.

Indexed as

DynaminsMitophagyAnimalsHistidineHypoxiaMiceNM23 Nucleoside Diphosphate KinasesUbiquitinationDnm1l protein, mouseDynaminsHistidineNM23 Nucleoside Diphosphate KinasesNme3 protein, mouse

Identifiers

PMID38480688
PMCPMC10938004
OpenAlexW4392761827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.